Healthcare Sector in India Monthly Update June 2012
Top Story Philips focusing on developing healthcare products for rural India Philips Electronics has decided to shift from its earlier exports–led strategy, and start focusing on developing healthcare products for rural India. Till about three years back, all the products manufactured by the company were meant for exports. Although this figure has come down marginally to 85% this year, the proportion of products developed for Indian markets is likely to go up. The focus will be on healthcare products for rural markets. At present, Philips’ healthcare division is developing products and low‐cost solutions used in cardiology, cervical cancer and mother and child‐care segments for rural markets. The healthcare team at Philips Innovation Centre is laying greater emphasis on making India‐focused, cost‐effective products. It is also working on telemedicine and decentralized healthcare and is looking to make products portable. The company partners with hospital chains to ideate new products relevant to India and also pilot the products. Its specialized R&D centre in Bangalore helps in ensuring affordability of these products.
Dr. Reddy’s and Merck inks JV for development of a Biosimilar Hyderabad based Dr. Reddy’s Laboratories Ltd. and Germany based Merck Serono, a division of Merck KGaA has entered into an alliance for development of a biosimilar compound. The biosimilar compound being developed is for oncological therapeutic segment with specific focus on monoclonal antibodies (MAbs). The deal is not only restricted to development of the compounds but also manufacture and worldwide commercialization of the product. The deal has been strategically designed wherein Dr. Reddy’s will initiate product development and complete Phase I development of the compound. Thereafter, Merck Serono will take over manufacturing of the compounds and will complete Phase III development of the compound. Dr. Reddy’s has already 4 biosimilar products to its credit and this joint venture will facilitate the company to establish its presence in emerging markets at a global level. The biotechnology industry has come into prominence in India and is one of the fastest growing knowledge‐based sectors. The biopharmaceutical industry captures the largest share of total revenue of the total biotechnology industry. Biotechnology industry is garnering attention due to rise in domestic business, increase in exports and new product innovations due to the various government initiatives to promote the sector.
Healthcare – Monthly Update
News Update General
Wipro bags HIS implementation contract for Manipal Health Enterprises Wipro Infotech, the IT solution provider of Wipro Ltd. has successfully bagged the deal of providing Hospital Information System (HIS) solution from Manipal Health Enterprises Private Limited. In the 10 years contract, Wipro will implement HIS solution and data migration services across 15 hospitals in 11 locations across 5 states of India of Manipal Group of hospitals. The HIS modules will enable systematic functioning of hospital and automation with organized data storage will ensure patients’ convenience. Piramal to reestablish pharma business Pirmal Healthcare Ltd. is in plans to re‐launch its pharmaceutical formulations business through mergers and acquisitions (M&A). The company has set up its reliable 3 member team to give direction to its plans. The team is in talks with Europe and USA based contract manufacturing companies that will enable expansion of its number of US FDA approved contract manufacturing plants. The company currently has 7 such plants in USA, Europe and India. Piramal had earlier sold its domestic drug formulations and diagnostic services business to US based Abott Laboratories in 2010 for INR 176 bn but retained its Contract research and manufacturing services (Crams), over‐the‐counter (OTC) and critical‐care product businesses. Lupin attains FDA approval for SUPRAX (Cefixime) Lupin Pharmaceuticals Inc. the wholly owned USA subsidiary of Lupin Ltd. has successfully acquired the US FDA approval of SUPRAX (Cefixime) 400 mg capsules that is used for the treatment of bacterial infections. With attainment of the approval, Lupin is in plans of initiating commercialization and shipment of the capsule at the earliest. The capsule is currently available in 100 mg/5ml and 200 mg/5ml suspensions as well as 400 mg tablets. Dr. Reddy’s launches Requip XL (R) bioequivalent Hyderabad based Dr. Reddy’s Laboratories declared its successful launch of Ropinirole Hydrochloride XR (Extended‐Release) tablets in the USA market after having gained approval from the US FDA. The tablet is the generic version of GlaxoSmithKline's Requip XL (R) tablets used in treatment of Parkinson’s disease. The tablets are available in 2 mg, 4 mg and 6 mg in 30 and 90 count bottle sizes while 8 mg and 12 mg are available in 30 count bottle sizes. Venus acquires patent for its new antibiotic product
Healthcare – Monthly Update
Haryana based Venus Remedies has been successful in acquiring patent for its new antibiotic product from the US Patent Office. The product CSE 1034 is a remedy for a wide range of drug resistant infections and particularly bacterial resistant mechanisms. The burgeoning problem of antibiotic resistance is driving regulatory agencies to scale up the approval process of antibiotic drugs. The product is expected to be launched in the brand name of Elores in India and is striving to achieve a speedy marketing approval from the US FDA. BoehringerEli Lilly jointly launches Linagliptin in India Boehringer Ingelheim and Eli Lilly’s alliance that was chalked out in Jan 2011 will launch its first product in India after its collaboration. Linagliptin, an oral drug for Type 2 diabetes in adults will soon be made available at chemist outlets. The drug is priced at INR 42.70 per dose. The drug is exceptional for its “renal‐friendly” nature and ability to control possible weight gain and low‐sugar attack on patients. The products are being priced in accordance to Indian market affordability and the companies will be sharing the costs, profits and revenues. Mumbai hospital launches robotic surgery The Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute collaborated to launch robotic surgical system in the Mumbai located hospital. The surgery was launched at an event organized in the hospital and has been named as da Vinci Robotic Surgery. Robotic surgery is a preferred surgical system in comparison to the conventional keyhole or laparoscopic surgery. The surgical precision that robotic surgery ensures is the reason for its growing preference among surgeons. The surgery helps in translating the surgeon’s hand movements into micro movements of tiny instruments that helps in making smaller incisions and less blood loss with fast recovery of patients. Ranbaxy and Daiichi Sankyo collaborate to capture Venezuela market Daiichi Sankyo will start marketing and selling Ranbaxy Laboratories products in Venezuela as part of its hybrid business model. Under the hybrid business strategy, Ranbaxy will focus on generic medicine research both for itself and its parent firm, while the new drug discovery programme will be undertaken by Daiichi Sankyo. Daiichi Sankyo, a wholly owned subsidiary of Daiichi Sankyo Venezuela S.A. was till recently marketing the drugs through a local distributor in Venezuela. Through the new arrangement, Daiichi Sankyo will popularize Ranbaxy’s extensive portfolio of products‐ both innovative as well as established pharmaceuticals in Venezuela. Healthcare – Monthly Update
HPV vaccine clinical trial stalled due to faulty statistics The clinical trial of HPV vaccine is currently under the scanner due to faulty cervical cancer statistics maintained in our country. The HPV is a precautionary vaccination against human papillomavirus infection that is the root cause of most cases of cervical cancer in women. The clinical trial was being sponsored by PATH, an international health charity that had claimed that India is estimated to have the largest burden of cervical cancer in comparison to all other countries. Hence, the clinical trial was planned in the Gujarat – Andhra Pradesh area with a sample of 23,000 girls. However, the clinical trials are on hold because of a recent study that was conducted by Barts Health and London Medical School that found the cancer surveillance, registration and monitoring in India in general and Gujarat and Andhra Pradesh regions in particular were incomplete. This might result in uncertainty of the vaccine’s success rate in disease prevention. Clinigen – Accord join hands for clinical trial drug distribution UK based clinical trial supplies division of pharmaceuticals and services group, Clinigen has drawn an exclusive tie up with Accord Healthcare‐ the wholly owned subsidiary of Ahmedabad based Intas Pharmaceuticals. As per the agreement, Clinigen will be responsible of administering and distributing Accord’s oncology injectibles portfolio for clinical trials across Europe. Clinigen will be fully responsible of handling enquiries, order for receivables and distribute the products demanded by manufacturers, contract research organisations, clinical‐trial contract packagers and other specialist service providers who will be sourcing Accord’s products for clinical trials.
News Update Regulatory
AIIMS to roll out pharmacy retail outlet The All India Institute of Medical Sciences (AIIMS) will be rolling out a pharmacy retail shop within its campus following the guidelines of government of India's Jan Aushadhi Scheme for out patient department (OPD) patients. Procurement and distribution of medicines has been entrusted to a private company where only generic medicines will be available. Previously only life saving drugs was distributed by AIIMS only to its indoor patients. This time round, apart from providing free consultation, the institute is offering free medicines to its patients. It will also install software for monitoring the stock, sale and availability of medicines and help in internal quality checks and audits to monitor prescribing pattern of doctors. Healthcare – Monthly Update
Biosimilar drugs to have separate guidelines The department of biotechnology in collaboration with the drug regulator has formulated a fresh set of guidelines for biosimilar drugs industry. The lack of any standard regulations led to the drafting of customized guidelines stating specific requirements for pre‐marketing and post‐marketing data apart from guidelines for pre‐clinical and clinical trials for biosimilars. The draft has been finalized in consultation with other industry operators and will be soon placed in public domain for discussion and final approval. DGCI slows clinical trials in India The Drug Controller General of India (DCGI) cautiousness is resulting in difficult and delayed consent for phase I clinical trials in India. The DCGI has laid greater emphasis on safety of the subjects put under trial as a result of which if any application is found lacking on any aspect, it gets pending. This is resulting in domestic companies moving to foreign shores like China, Canada and Europe for carrying out the trials. This is resulting in deterrence of clinical trials business and taking a toll on the research and development efforts of Indian companies. DuBiotechIDMA to sign MoU Dubai Biotechnology and Research Park (DuBiotech) is soon to ink a memorandum of understanding (MoU) with the Indian Drug Manufacturers’ Association (IDMA). The MoU will throw open lucrative business opportunities for the Indian life sciences industry in the Middle East market through the DuBiotech free trade zone. The MoU will be signed by Marwan Abdulaziz, the executive director of DuBiotech and Dr. Manish Doshi, president of IDMA in Mumbai on Jun 15, 2012. The DuBiotech Life Sciences has developed the best biomedical and pharmaceutical infrastructure and the association is expected to assist Indian companies to help better accessibility with institutions and companies with whom they can collaborate for shared benefits. Delhi government to initiate operations of super specialty hospitals Two new super specialty hospitals Janakpuri Super Specialty and Rajiv Gandhi Super Specialty are soon to start its operation after it is commissioned with the Delhi government. The hospitals will be operated through a "society set up" headed by Chief Secretary of Delhi and assisted by top officials of Union Health Ministry. The hospitals that were ready 3 years back in 2009 failed to start operations due to fall out of the public private partnership (PPP) model that was decided upon. The Janakpuri and Rajiv Gandhi Super Specialty hospitals each having 1000 bed capacity will provide specialised health care facilities in areas of cardiology, Healthcare – Monthly Update
nephrology, urology, cancer, renal transplant, gastroenterology, radiology, pathology and microbiology. Odisha government lays down plans for Tata’s CSR The Odisha state government has proposed the Tata Group to set up a hospital in the state as part of its corporate social responsibility (CSR) in a meeting between Tata Son's deputy chairman Cyrus Pallonji Mistry and state government minister Naveen Patnaik. The government has recommended Tata group to set up a 400 bedded hospital in Ganjam district that lies in the Andhra Pradesh‐ Odisha border. Apart from setting up of the hospital, the government has even urged the setting up of 4 placement‐linked Industrial Training Centres for multi skill development of the state local youths. Odisha government’s careful planning is expected to bring relief for the less privileged section of the state. Odisha cancer centre set for an overall up gradation One of the very well reputed cancer centre of the country, Acharya Harihar Regional Cancer Centre located at Cuttack, Odisha is set to undergo a phenomenonal change to acquire the status of an apex healthcare facility. The centre is due to receive a lump some financial aid as per the 12th Five Year Plan. The cancer centre will see an increase in bed strength from 216 to 320 with an increase in number of doctors and para medic staff. The cancer centre is also expected to install advanced equipments like Positron Emission Tomography (PET) scanner for diagnosis and treatment of the fatal disease. Odisha’s lack in upgraded devices will be solved by the revamping of Acharya Harihar Regional Cancer Centre to bring the state’s health infrastructure at par with other states of the country. Chattisgarh government to solve drug accessibility issues Chattisgarh state government has approached all state district hospitals to sell generic drugs to solve drug accessibility issues in the region. The decision has been specifically taken to ensure availability of drugs to the under privileged at a price that is less by at least 30% to 40% in comparison to its branded counterparts. The chief minister has issued an order to the State Health Department to implement the plan within a span of 15 days. In an attempt to realize the plan, the hospital located in Surguja district has already inaugurated a generic drug store last month. The facility will soon be initiated in Ambedkar hospital in Raipur along with other district hospitals where there are medical stores operating under Red Cross. The Chattisgarh state government is expected to solve issues related to drug accessibility in the region along with popularizing generic drugs. Healthcare – Monthly Update
Drug marketing code soon to regulate drug prescription The Department of Pharmaceuticals in an attempt to curb violation of regulatory norms with regard to drug prescription will soon initiate the ‘drug marketing code’ norm. In order to discuss the proposal and its plan of action, the Department of Pharmaceuticals will have a meeting on Jul 18, 2012 with the Medical Council of India. The step has been taken in an attempt to negate the practice of pharmaceutical companies endowing doctors with incentives in return of prescribing the company’s drugs.
News Update Expansion Plans
Trivitron Healthcare expands into Critical Life Support Solution segment Trivitron Healthcare has forayed into the Critical Life Support Solution (CLSS) space. The company is expanding its presence in the segment which includes solutions and products for intensive care, operating room, dialysis care and cardiac care solutions. Trivitron believes that operating room and intensive care are the most essential and basic needs for any corporate hospital and hence the new segment will serve as a long term prospect for the company. CLSS comprises one‐third of the INR 170 bn medical equipments and devices market. Trivitron which had group revenues in excess of INR 4 bn in 2011‐12 is expected to become an INR 5 bn company in 2012‐13 after its foray into the CLSS segment. Philips starts production of healthcare devices at its new facility near Pune Philips Electronics India Ltd. has started production at its geenfield healthcare manufacturing facility in Chakan, near Pune. This is the company’s sixth centre of excellence in the world after Netherlands, Germany, China, USA and Israel. The new facility is being used for the production of diagnostic imaging systems targeting cardiology (catheterization laboratories) and radiology (general X‐ray) applications, first for the Indian market and then for global markets. The company believes that in order to make a difference in the Indian market, it will need local expertise, low‐cost manufacturing capacity and maintain close relationships with customers. The Pune facility is producing X‐ray and cath lab equipments that are affordable for tier II and tier III towns and rural markets. Many of the products developed in the Pune plant can also serve the needs of mature markets looking to replace or upgrade entry level diagnostic devices.
Healthcare – Monthly Update
Elder Ferrer launches Zalain in India Mumbai based Elder Pharmaceuticals Ltd. and Spain based drug firm Ferrer has successfully launched an antifungal remedy in the Indian market. The medicine Zalain is a treatment meant for anti fungal skin infections. The product has been launched with the sole purpose of strengthening Elder’s anti infective segment. Elder Pharmaceuticals is also planning to launch 5 other products in its nutraceutical segment in association with international firms within a span of 6 months in the Indian market. Narayana Hrudayalaya steps into Assam through PPP Bangalore based Narayana Hrudayalaya Hospitals Pvt. Ltd. (NHHPL) has inked a Memorandum of Understanding (MoU) with Assam state government for setting up of a hospital. The NHHPL will be setting up an INR 1.5 bn worth super specialty hospital in Amingoan, near Guwahati based on a public private partnership (PPP) model. The Assam state government selected NHHPL as its private partner through a transparent bidding process. The state government would be contributing a sum of INR 0.55 bn towards the venture. In the MoU, Assam government has put forth its decision of charging 1.85% below Central Government Health Scheme (CGHS) rates for not less than 50% of all beds inclusive of different wards, ICU, ITU, ICCU, OPD as well as diagnostics. The hospital will prove to be very beneficial for patients in north eastern region of India as well as for neighbouring countries of Bhutan and Bangladesh. India soon to have its first Japanese hospital Japan based security and medical service provider Secom Company is in plans to establish a hospital in Bangalore, thereby becoming the 1st Japanese company operating a hospital in India. The company will be setting up the hospital through a joint venture with Kirloskar group and Toyota Tsusho Corporation. The general hospital will have provision of 300 beds and will be equipped with latest technologies. Seacom will bear 40% of the capital requirement, while Kirloskar and Toyota Tsusho Corporation will bear 34.6% and 25.4% respectively. The growing demand for advanced healthcare services from middle to high income earners in India is drawing significant attention from both national and international companies. KIMS launches Royal Bahrain Hospital in Bahrain Kerala Institute of Medical Sciences (KIMS) group has launched the KIMS Royal Bahrain Hospital (KIMS‐RBH) in Bahrain. It happens to be Bahrain’s 1st customized private hospital with facilities like operational sleep lab, advanced laser technology for cosmetic surgery and foetal medicine treatment. The INR 900 mn project has been sponsored by the businessmen of the 2 countries and has been bestowed a special Indo‐Bahraini project status by the Economic Development Board (EDB). Healthcare – Monthly Update
The hospital comes after KIMS Bahrain Medical Center (KBMC) and is KIMS’s 6th project in the Gulf Co‐operation Council region. The Gulf region is proving to be a good investment ground for KIMS that is envisaging the setting up of more such units the region.
Wipro bags HIS implementation contract for Manipal Health Enterprises – Dr. Nagendra Swamy, President and Chairman, Quality Council, Manipal Health Enterprise "The HIS implementation initiative will help Manipal Hospitals in improving Quality of Service Delivery by the way of process standardization and automation, improving patient satisfaction by reducing waiting time & hence improving overall efficiency of Hospital Operations. Quality is an integral aspect with regards to achieving service delivery standards and going forward we would like to have the benefit of the analytics that can be mined from the HIS and develop into actionable strategies. One of the benefits of having a state of the art HIS is improved monitoring of drug usage and study of effectiveness. This leads to the reduction of adverse drug interactions and thus addresses a major patient safety parameter" Dr. Reddy’s and Merck inks JV for development of a Biosimilar – G. V. Prasad, ViceChairman and CEO, Dr. Reddy’s Laboratories “We strongly believe that biosimilars is an important area of future growth and these products give us the opportunity to provide affordable and innovative medicines to patients across the globe. With the recent EMA and FDA guidance on biosimilars, it is clear that any significant player in the field will need strong biologics development, manufacturing and commercialization capabilities. Merck Serono’s and Dr. Reddy’s joint expertise in these fields makes for a powerful global partnership.”
Medical Devices : Transactions (Apr 2012 – Jun 2012)
Date
Buyer
Target
Deal Size (INR mn)
% stake
Deal Status
Type of Transaction
4th Apr 2012
CX Partners
Sutures India
2000
40
Planned
Private Equity
Healthcare – Monthly Update
Biotech and Pharmaceutical : Transactions (Apr 2012 – Jun 2012) Date
Buyer
Target
Deal Size (INR mn)
% stake
Deal Status
Type of Transaction
14th Jun 2012
Jacob Ballas Capital & IFC
Super Religare Laboratories (Fortis Healthcare)
3700
N.A.
Planned
Private Equity
16th May 2012
Piramal Healthcare Ltd.
Decision Resources Group
34000
N.A.
Planned
M&A
16th May 2012
Tano Capital
Shilpa Medicare Ltd.
100
N.A.
Completed
Private Equity
26th Apr 2012
Sterile Arcolab Ltd.
Star Drugs’ and Research Lab Ltd.
1250
100%
Completed
M&A
25th Apr 2012
ChrysCapital
Intas Pharmaceuticals
3000
Above 15%
Planned
Private Equity
2nd Apr 2012
Advent International Corp.
Care Hospitals Pvt. Ltd.
5600
N.A.
Completed
Private Equity
Medical Devices : Annual Financial Results – Revenue (INR mn) Companies
FY ’09
FY ’10
FY ’11
FY’ 12
Blue Star Ltd.
25,026.2
25,249.7
29,536.8
27,888.5
BPL Limited
1,293.117
1,185.283
2,296.66
771.216
295.262
304.853
425.648
N.A.
8,185.197
10,775.826
15,855.631
23,568.543
Maestros Mediline Systems Ltd. Opto Circuits (India) Ltd.
Healthcare – Monthly Update
Shree Pacetronix Limited Siemens India Ltd.
59.139
62.078
57.656
N.A.
93,070.2
96,272.4
119,718.1
N.A.
Medical Devices : Quarterly Financial Results – Revenue (INR mn)
AprJun 2011
JulSep 2011
OctDec 2011
JanMar 2012
Blue Star Ltd.
N.A.
N.A.
5,896.9
N.A.
Maestros Mediline Systems Ltd.
N.A.
130.265
81.637
N.A.
5,208.2
5,620.4
6,112.9
6,627.0
N.A.
N.A.
N.A.
37601.432
Companies
Opto Circuits (India) Ltd. Siemens India Ltd.
Medical Devices : Annual Financial Results – Income (INR mn)
Companies
FY ’09
FY ’10
FY ’11
FY’ 12
Blue Star Ltd.
1,802.9
2,114.9
1,609.6
(1,051.0)
BPL Limited
39.431
(33.722)
758.37
579.833
Maestros Mediline Systems Ltd.
2.547
5.976
36.701
N.A.
Opto Circuits (India) Ltd.
2,087.3
2,603.0
3,672.5
5,718.8
Shree Pacetronix Limited
1.586
1.11
(2.367)
N.A.
7,046.0
7,577.7
8,677.5
N.A.
Siemens India Ltd.
Healthcare – Monthly Update
Medical Devices : Quarterly Financial Results – Income (INR mn)
AprJun 2011
JulSep 2011
OctDec 2011
JanMar 2012
Blue Star Ltd.
N.A.
N.A.
(327.6)
N.A.
Maestros Mediline Systems Ltd.
N.A.
9.018
3.957
N.A.
1,163.9
1,210.6
1,250.8
2,093.5
N.A.
N.A.
N.A.
3040.035
Companies
Opto Circuits (India) Ltd. Siemens India Ltd.
Biotech and Pharmaceutical : Annual Financial Results – Revenue (INR mn) Companies
FY ’09
FY ’10
FY ’11
FY’ 12
Abott India Ltd.
7,822.70
9,406.60
14,772.4
16,050.1
Ajanta Pharma Ltd.
3,493.40
4,091.40
5,048.70
6,713.8
11,190.28
11,399.17
2,007.84
14,623.5
906.73
897.79
1,054.09
1,150.23
Biocon Ltd.
16,492.50
23,932.70
27,947.70
21,483.0
Cadila Healthcare Ltd.
29,066.00
35,780.00
44,671.00
50,899.7
Cipla Ltd.
52,876.20
56,704.00
63,850.70
68,477.0
Claris Lifesciences Ltd.
7,435.30
7,523.40
7,387.7
7,624.6
Dabur India Ltd.
28,122.40
33,958.00
40,817.40
52,832.0
Divi's Laboratories Ltd.
11,849.50
9,499.20
13,137.00
18,585.9
69,441.00
70,277.00
74,693.00
96,737.4
6,242.30
7,284.10
9,648.50
13,237.9
Alembic Pharmaceuticals Ltd. Amrutanjan Health Care Ltd.
Dr. Reddy’s Laboratories (DRL) Elder Pharmaceuticals Ltd.
Healthcare – Monthly Update
FDC Ltd.
5,909.00
6,340.10
7,103.30
7,073.6
3,257.20
4,884.80
5,255.60
5,243.2
19,757.6
23,693.3
27,688.6
28,857.3
19,179.80
21,608.50
23,893.4
N.A.
21,241.20
25,291.30
29,490.70
40,206.4
Hikal Ltd.
5,728.70
5,389.50
5,023.00
7,078.2
Intas Pharmaceuticals Ltd.
11,266.20
16,172.30
17,541.7
N.A.
Jubilant life Sciences Ltd.
35,491.00
38,047.80
34,484.40
42,539.5
Lupin Ltd.
38,508.30
48,318.10
57,851.90
70,829.1
Morepen Laboratories Ltd.
1,854.80
2,121.80
2,293.40
2,810.0
Nestle India Ltd.
51,395.5
62,609.4
74,994.6
77,409.0
Panacea Biotec Ltd.
7,921.80
9,066.70
11,573.50
6,978.0
Pfizer Ltd.
7,944.1*
N.A.
9,326.10
10,173.0
32,478.20
36,276.30
25,157.70
20,838.3
12,459.00
15,121.10
16,413.8
16,651.2
75,970.40
89,607.70
101,614.1
117,153.2
13,101.6
16,958.4
25,245.2
25,645.1
42,723.00
38,086.30
57,214.30
80,056.6
16,306.60
19,160.40
22,264.80
26,959.2
3,708.40
4,924.10
6,709.20
7,026.3
816.032
868.02
957.01
898.06
18.23
8.014
56.75
36.22
3,6294.4*
36,477.60
37,633.50
46,138.0
Fresenius Kabi Oncology Ltd. GlaxosmithKline Consumer Heathcare ltd. GlaxoSmithKline Pharmaceuticals Ltd. Glenmark Pharmaceuticals Ltd.
Piramal Healthcare Ltd. Plethico Pharmaceuticals Ltd. Ranbaxy Laboratories Ltd. Strides Arcolab Ltd Sun Pharmaceuticals Industries Ltd. Torrent Pharmaceuticals Ltd Twilight Litaka Pharma Ltd. Vimta Labs Ltd Vista Pharmaceuticals Wockhardt Ltd.
Healthcare – Monthly Update
Zandu Realty Ltd.
877.46
N.A.
N.A.
700.00
Biotech and Pharmaceutical : Quarterly Financial Results – Revenue (INR mn) Companies
AprJun 2011
JulSep 2011
OctDec 2011
JanMar 2012
Abott India Ltd.
3,514.20
3,968.90
4,102.70
3,664.4
Ajanta Pharma Ltd.
1,273.10
N.A.
1,639.00
2,450.5
Alembic Pharmaceuticals Ltd.
3,432.7
3,969.6
3,813.3
3,407.9
Amrutanjan Health Care Ltd.
N.A.
N.A.
N.A.
N.A.
Biocon Ltd.
4,416.80
5,084.40
5,171.90
5,892.2
Cadila Healthcare Ltd.
11,735.10
12,196.40
13,524.60
13,443.6
Cipla Ltd.
15,914.20
N.A.
17,580.00
N.A
Claris Lifesciences Ltd.
1,916.70
2,040.90
1,863.6
1,803.5
Dabur India Ltd.
12,045.80
12,623.30
14,526.80
13,858.3
Divi's Laboratories Ltd.
3,585.50
N.A.
4,174.20
7,180.4
Dr. Reddy’s Laboratories (DRL)
19,783.00
22,678.00
27,692.00
26,584.0
Elder Pharmaceuticals Ltd.
2,996.60
3,310.80
3,431.2
3,453.9
FDC Limited
1,823.2
N.A.
1,636.6
N.A.
N.A.
N.A.
1,283.20
N.A.
Fresenius Kabi Oncology Ltd. Glaxosmithkline Consumer Healthcare Ltd. GlaxoSmithKline Pharmaceuticals Ltd. Glenmark Pharmaceuticals Ltd.
6,533.8
7,200.7
6,854.0
8,608.7
5,615.40
6,146.20
N.A.
N.A.
8,682.50
10,554.50
10,310.90
10,658.6
Hikal Ltd.
1,428.00
N.A.
1,854.80
N.A.
Healthcare – Monthly Update
Intas Pharmaceuticals Ltd.
N.A.
N.A.
N.A.
N.A.
Jubilant life Sciences Ltd.
9,442.90
10,480.80
10,871.70
11,711.0
Lupin Ltd.
15,677.40
17,723.90
18,189.30
19,238.5
602.1
N.A.
711.1
729.2
Nestle India Ltd.
17,630.50
19,631.00
19,633.2
20,558.7
Panacea Biotec Ltd.
2,209.90
N.A.
1,551.60
N.A
Pfizer Ltd.
2,418.70
2,718.20
2,518.80
2,517.3
Piramal Healthcare Ltd.
4,350.00
4,775.80
5,518.30
8,858.0
Plethico Pharmaceuticals Ltd.
4,545.7
4,121.0
4150.1
3,638.8
Ranbaxy Laboratories Ltd.
20,931.2
20,955.3
37,923.1
36,954.0
Strides Arcolab Ltd
5,812.50
7,693.10
6,864.7
5,274.7
Sun Pharmaceuticals Industries Ltd.
16,357.20
18,946.00
21,451.30
23,299.3
Torrent Pharmaceuticals Ltd
6,133.9
6,833.3
6,965.9
6,743.3
Twilight Litaka Pharma Ltd.
1,835.60
N.A.
1,867.20
N.A.
Vimta Labs Ltd
245.44
202.42
201.52
224.07
Vista Pharmaceuticals
11.461
N.A.
5.10
15.24
10,532.10
11,105.30
12,086.70
12,413.90
N.A.
N.A.
N.A.
700.00
Morepen Laboratories Ltd.
Wockhardt Ltd. Zandu Realty Ltd.
Biotech and Pharmaceutical : Annual Financial Results – Income (INR mn) Companies
FY ’09
FY ’10
FY ’11
FY’ 12
Abott India Ltd.
775.1
753.0
1,203.9
1,415.3
Healthcare – Monthly Update
Ajanta Pharma Ltd.
254.3
340
507.1
772.7
Alembic Ltd.
108.17
395.378
‐129.019
1,301.4
Amrutanjan Health Care Ltd.
923.94
114.72
102.12
127.10
Biocon Ltd.
931.2
2,932.40
3,675.20
3,384.0
Cadila Healthcare Ltd.
3,031.00
5,051.00
7,110.00
6,525.9
Cipla Ltd.
7,710.20
10,825.90
9,895.70
11,442.4
Claris Lifesciences Ltd.
1,303.70
1,414.40
1,262.6
1,280.5
Dabur India Ltd.
3,905.00
5,010.80
5,685.70
6,449.0
Divi's Laboratories Ltd.
4,166.40
3,403.40
4,292.70
5,332.6
Dr. Reddy’s Laboratories (DRL)
‐5,168.00
1,068.00
11,040.00
14,262.1
Elder Pharmaceuticals Ltd.
608.3
495.0
642.2
759.6
FDC Ltd.
862.1
1,491.30
1,508.90
1340.9
‐1,460.20
‐333.6
160.1
509.5
Glaxosmithkline Consumer Healthcare Ltd.
2,327.8
2,998.5
3,552.1
3,765.6
GlaxoSmithKline Pharmaceuticals Ltd.
5,078.60
5,605.70
4,285.9
N.A.
Glenmark Pharmaceuticals Ltd.
1,916.60
3,244.70
4,532.10
4,603.5
405
72.9
370.2
460.4
923.2
2,058.20
2,079.7
N.A.
Fresenius Kabi Oncology Ltd.
Hikal Ltd. Intas Pharmaceuticals Ltd.
Healthcare – Monthly Update
Jubilant life Sciences Ltd.
2,831.80
4,214.60
2,297.20
145.6
Lupin Ltd.
5,015.40
6,816.30
8,625.50
8,676.5
Morepen Laboratories Ltd.
‐417.6
‐62.2
‐469.4
‐236.5
Nestle India Ltd.
6,550.0
8,186.6
9,615.5
9,815.7
Panacea Biotec Ltd.
‐654.8
817.2
1,446.70
‐2,056.5
Pfizer Ltd.
1,371.2*
N.A.
1,697.60
1,846.1
Piramal Healthcare Ltd.
3,162.50
4,819.00
128,833.60
1,115.0
Plethico Pharmaceuticals Ltd.
2,169.30
2,444.00
1,029.1
951.1
Ranbaxy Laboratories Ltd.
2,964.90
14,967.50
‐28,997.3
‐19,573.5
Strides Arcolab Ltd
1,096.80
1,224.50
2,244.8
8,258.4
Sun Pharmaceuticals Industries Ltd.
18,177.30
13,510.80
18,160.60
25,872.5
Torrent Pharmaceuticals Ltd
1,843.70
2,312.00
2,701.70
2,840.4
Twilight Litaka Pharma Ltd.
219.4
326.3
512.5
515.4
Vimta Labs Ltd
40.443
26.586
‐46.651
‐119.99
‐9.62
‐13.50
‐2.92
‐15.26
‐4,355.4*
‐9,804.20
905.2
3,427.1
152.55
13.91
9.14
‐702.82
Vista Pharmaceuticals Wockhardt Ltd. Zandu Realty Ltd.
Healthcare – Monthly Update
Biotech and Pharmaceutical : Quarterly Financial Results – Income (INR mn) Companies
AprJun 2011
JulSep 2011
OctDec 2011
JanMar 2012
Abott India Ltd.
171.0
436.3
368.8
270.8
Ajanta Pharma Ltd.
125.3
N.A.
185.1
343.7
Alembic Pharmaceuticals Ltd.
275.6
380.4
442.3
203.1
Amrutanjan Health Care Ltd.
N.A.
N.A.
43.17
N.A
700.5
857.0
848.50
978.0
Cadila Healthcare Ltd.
2,298.20
1,026.80
1,492.10
1,708.8
Cipla Ltd.
2,533.40
N.A.
2,699.10
N.A.
377.2
340.1
346.3
216.9
Dabur India Ltd.
1,277.4
1,738.6
1,728.20
1,705.1
Divi's Laboratories Ltd.
1,025.90
N.A.
1,225.50
2,169.10
Dr. Reddy’s Laboratories (DRL)
2,627.0
3,078.0
5,130.0
3,427.0
201.2
193.5
182.9
142.9
FDC Ltd.
344
N.A.
329
N.A.
Fresenius Kabi Oncology Ltd.
N.A.
N.A.
14
N.A.
824.6
1,030.3
591.0
1,319.7
1,475.40
1,458.60
N.A.
N.A.
2,101.10
558.6
461.20
1,503.6
Hikal Ltd.
145
N.A.
130.4
N.A.
Intas Pharmaceuticals Ltd.
N.A.
N.A.
N.A.
N.A.
771.2
793.6
‐783.90
635.3
Biocon Ltd.
Claris Lifesciences Ltd.
Elder Pharmaceuticals Ltd.
Glaxosmithkline Consumer Healthcare Ltd. GlaxoSmithKline Pharmaceuticals Ltd. Glenmark Pharmaceuticals Ltd.
Jubilant life Sciences Ltd.
Healthcare – Monthly Update
Lupin Ltd.
2,100.80
2,668.70
2,350.60
1,556.4
‐131.3
N.A.
‐90.6
68.1
2,138.30
2,611.80
2,308.30
2,757.3
Panacea Biotec Ltd.
167.2
N.A.
‐717.2
N.A.
Pfizer Ltd.
412.4
469.9
482.8
481.0
Piramal Healthcare Ltd.
892.3
524.3
85.2
‐386.8
Plethico Pharmaceuticals Ltd.
743.6
385.9
‐652.8
474.4
2,432.4
‐4,645.8
‐29,827.7
12,467.6
688.9
464.7
684.1
6,420.7
Sun Pharmaceuticals Industries Ltd.
5,010.0
5,977.4
6,683.0
8202.1
Torrent Pharmaceuticals Ltd
1,025.20
999.9
831.8
‐16.5
Twilight Litaka Pharma Ltd.
128.2
N.A.
93.8
N.A.
Vimta Labs Ltd
‐14.44
‐33.97
‐37.70
67.65
Vista Pharmaceuticals
‐2.69
N.A.
‐4.49
‐0.66
1,939.60
1,275.80
2,128.10
‐1,916.4
1.93
3.21
11.68
‐719.66
Morepen Laboratories Ltd. Nestle India
Ranbaxy Laboratories Ltd. Strides Arcolab Ltd
Wockhardt Ltd. Zandu Realty Ltd.
Events Calendar PharmaLytica India 2012 th Jul – 20th Jul 2012 Date: 18 Venue: Mumbai, Maharashtra Website: ww w.pharmalyticaindia.com Contact No.: +91‐22‐4046 1466
NextGen 2012: Advances in Pharma and Biopharma Drug Delivery Date: 25th Jul – 27th Jul 2012 Venue: Mumbai, Maharashtra Website: www.nextgenin.com Contact No.: +91‐22‐4046 1466
Healthcare – Monthly Update
Research on India (ROI) is a leading source for market research on various sectors in India that offers premium research content from worldwide publishers of market research reports. Contact us: W: https://www.researchonindia.com T: India (Toll Free): 1800 102 1133; International: +91 (33) 4027 6214/5 E: support@researchonindia.com Connect with Us Disclaimer: This monthly update is published for general information only based on press articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document.
Healthcare – Monthly Update